The study underscores the viability of GnRH-DFF40 for targeted breast cancer treatment, presenting a promising candidate for further clinical investigation due to its selective toxicity towards GnRH receptor-positive cancer cells [228]. This evidence concerns the gene GNRH1 and breast carcinoma.